Latest Gossamer Bio News & Updates

See the latest news and media coverage for Gossamer Bio. We track all announcements, press releases, and industry mentions in real time, all in one place.

Gossamer Bio

Clinical-stage biopharmaceutical company developing therapies for pulmonary hypertension

gossamerbio.com

Headquarters: San Diego, United States
Founded year: 2017
Company type: Public company
Number of employees: 125–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Gossamer Bio

In short: Gossamer Bio planned a September 2026 NDA for seralutinib, secured $250 million in funding, and implemented a 1-for-80 reverse stock split.

Company announcements

September 9 Gossamer Bio

Gossamer Bio executes 1-for-80 reverse stock split

The company aims to regain Nasdaq compliance by raising the minimum bid price requirement. Trading begins on September 11 under symbol GOSS with adjusted share ratios.

August 13 Gossamer Bio

Gossamer Bio announces second quarter 2026 financial results

Plans NDA submission for September 2026 after FDA meeting, reacquired global seralutinib rights from Chiesi, and reported Q2 net income of $16.9 million.

July 27 Gossamer Bio

Gossamer Bio announces FDA update and reacquires seralutinib rights

The company plans to submit an NDA for seralutinib in PAH in September 2026, reacquired worldwide rights from Chiesi, and reported cash of $57 million.

June 17 Gossamer Bio

Gossamer Bio announces final tender results for exchange offer

The exchange offer for $181M in existing notes closed early, with $18.9M remaining outstanding.

Media coverage

Yesterday MSN

Gossamer Bio consensus price target increased by 4,500% to $135.13

The average one-year price target for Gossamer Bio (NASDAQGS:GOSS) has been revised to $135.13 / share. This is an increase of 4,500.00% from the prior...

September 9 Financial Times

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split

In connection with the reverse stock split, the number of authorized shares of the Company’s common stock was reduced from 4,000,000,000 to 50,000,000, and the...

September 6 Börse Express

Gossamer Bio stock: financing of over 250 million agreed

Gossamer Bio prepares the seralutinib application, secures up to 250 million US dollars and reduces its capital debt by 115.9 million.

August 28 Stock-World

Gossamer Bio stock: $125 million following FDA approval

Gossamer Bio receives capital commitments for Seralutinib, while $125 million remains tied to the FDA approval application.

Never miss news about Gossamer Bio

Track Gossamer Bio and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.